Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 17/20 | 0.76 |
| ▸ | KDR | P35968 | 17/20 | 0.76 |
| ▸ | HCK | P08631 | 15/20 | 0.76 |
| ▸ | SRC | P12931 | 13/20 | 0.76 |
| ▸ | PLK4 | O00444 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | FYN | P06241 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | FES | P07332 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | LYN | P07948 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587520 | 0.87 | LCK (1.00) | LCKKDRHCKSRCABL1 | |
| SCHEMBL3591970 | 0.86 | LCK (0.80) | LCKKDRHCKSRCABL1 | |
| SCHEMBL13503290 | 0.82 | KDR (0.71) | LCKKDRHCKSRCPLK4 | |
| SCHEMBL13503293 | 0.79 | LCK (0.81) | LCKKDRHCKSRC | |
| SCHEMBL3590786 | 0.77 | LCK (0.85) | LCKKDRHCKSRCABL1 | |
| SCHEMBL3589588 | 0.77 | LCK (0.70) | LCKKDRHCKSRCABL1 | |
| SCHEMBL4177466 | 0.76 | LCK (1.00) | LCKKDRHCKSRC | |
| SCHEMBL13503283 | 0.76 | LCK (0.85) | LCKKDRHCKSRC | |
| SCHEMBL3593879 | 0.75 | KDR (0.62) | LCKKDRHCKSRCABL1 | |
| SCHEMBL13503276 | 0.75 | LCK (0.83) | LCKKDRHCKSRCABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | LCK 1/4885KDR 1630/4885HCK 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.